written on 18.11.2016

Nominees for Prix Galien Russia 2016 announced


Laureates to be recognized by Research and Academic Leaders at Awards Ceremony on December 1st in Moscow

Moscow (Nov 17th, 2016) —The organizers of Prix Galien Russia have today released the nominees for the third edition of the Awards.

The Prix Galien Russia Committee (or Jury) comprises 15 renowned leaders in biomedical research and academia and is responsible for evaluating nominees based on scientific files. Laureates will be honored at the Prix Galien Russia Awards Ceremony at Volkhonka Mansion, on the 1st of December 2016

The Prix Galien Russia Committee designates a laureate in 6 different categories by evaluating scientific applications files submitted by the candidates based solely on two questions:

  1. What was innovative in the course of this product’s or research program’s scientific development, application and/or clinical utility?
  2. What was learned for the future of biomedical science from this product’s introduction to the clinic or from the research program?

Frederic Boucheseiche, General Secretary of Prix Galien Russia, reiterated the uniqueness and importance of Prix Galien by emphasizing the fact that the Jury’s decision is based only on scientific and medical criteria, that marketing and commercial considerations never enter into the Jury’s decision, and by restating that pharmaceutical companies cannot sponsor the event.

“Organizing an awards ceremony under such strict principles is extremely challenging, but this is the condition that guarantees the impartiality of the jury’s decision. Prix Galien Russia uses the same strict criteria as in all other countries where the award is held, making its legitimacy indisputable.” Frederic Boucheseiche.

Nominees for the Prix Galien Russia 2016 Awards are:

Best Orphan Drug (Nominees)

Opsumit® – Actelion Pharmaceuticals RUS, Ltd

Blinatumobab – Amgen

Best Pharmaceutical Agent (Nominees)

Forxiga  – AstraZeneca

Lynparza – AstraZeneca

Viekira Pak – Abbvie

Otezla – Celgene

Imbruvica – Janssen, Pharmaceutical companies of Johnson & Johnson

FORSTEO® – Eli Lilly

Trulicity – Eli Lilly

Best Biotechnology Product (Nominees)

Evolocumab – Amgen

YERVOY® – Bristol-Myers Squibb

Sovriad – Janssen, Pharmaceutical companies of Johnson & Johnson

Zelboraf – Roche / R-Pharm

Beyodym – Roche / R-Pharm

Best Medical Technology (Nominees)

Absorb – Abbott

OneTouch Verio® IQ  – Johnson & Johnson

Best Research in Russia (Nominees)

Development of a new generation of Antivirals of the family of azoloazines – Institute of Organic Synthesis

Nanoencapsulated colistin – BIND (RUS) LLC

Mobilan – Panacela Labs

OncoFinder platform for personalized selection of drugs in oncology – First Oncology Research and Advisory Center

Best Russia Product (Nominees)

ImmunoQuantex  “Femoflor®”+ «ImmunoQuantex” – DNA-Technology LLC/ Federal State Budget Institution “Research Center for Obstetrics, Gynecology and Perinatology” Ministry of Healthcare of the RF

Seroguard – JSC “Pharmasyntez”

Triazavirin – MEDSYNTHEZ

Prix Galien Jury

Prof. Sergey Olegovich Bachurin

Prof. Sergey Anatolievich Boytsov

Prof. Vladimir Trofimovich Ivashkin

Prof. Eugeny Lvovich Nasonov

Prof. Rem Viktorovich Petrov Профессор

Prof. Dmitry Yurievich Pushkar

Prof. Gennady Tikhonovich Sukhikh

Prof. Evgeny Davidovich Sverdlov

Prof. Michael Veniaminovich Ugrumov

Prof. Valery Mikhailovich Zaiko

Prof. Amiran Shotaevich Revishvili

Prof. Khristo Periklovich Takhchidi

Prof. Altksey Izrailevich Mazus

Prof. Igor Evgenievich Khatkov

Prof. Igor Evgenievich Tyurin

General Secretary Frederic Boucheseiche

About Prix Galien Russia:

Prix Galien Russia was inaugurated in Moscow in 2013 under the auspice of an exceptional awards committee composed of eminent specialists involved in the sphere of Russian and international pharmaceutical research.

A Prix Galien Award is considered the biomedical industry’s highest accolade and recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines.

Around the world, Prix Galien rewards outstanding achievements in improving the global human condition through the development of innovative therapies. Created in France 40 years ago, Prix Galien has selection committees in 16 countries around the world.

More information on: http://prixgalienrussia.com